Cargando…

Evusheld™ Pre-Exposure COVID-19 Prophylaxis in Pediatric Hematopoietic Stem Cell Transplant (HSCT) and Cellular Therapy Recipients: A Single Institution Retrospective Series

Detalles Bibliográficos
Autores principales:	DePriest, Brittany Paige, Heh, Julie, Donahoo, Lori Burton, Jaroscak, Dr. Jennifer Joi, Hudspeth, Michelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. 2023
Materias:	Poster Session: Infectious Diseases and Cytotoxic T Lymphocytes
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899539/ http://dx.doi.org/10.1016/S2666-6367(23)00520-1

Ejemplares similares

‘Real-World’ Impact of Tixagevimab/Cilgavimab (Evusheld) on COVID-19 Outcomes in Patients Undergoing Cellular Therapies
por: Sannareddy, Aishwarya, et al.
Publicado: (2023)

Impact of COVID-19 Pandemic on Hematopoietic Stem Cell Transplantation (HSCT) and Immune Effector Cell (IEC) Therapies: A Large US Cancer Center Experience
por: Maurer, Katie, et al.
Publicado: (2021)

Favorable Outcomes of Pediatric Hematopoietic Cell Transplant Patients Receiving Regen-COV2 for Prophylaxis Against Severe COVID-19 Disease
por: Graham, Rudi-Ann Tamara, et al.
Publicado: (2022)

Immunogenicity and Safety of a Heterologous COVID-19 Vaccine Regimen in Hematopoietic Stem Cell Transplant Recipients
por: Fatobene, Giancarlo, et al.
Publicado: (2023)

Outpatient Treatment with Anti-Sars-Cov-2 Monoclonal Antibodies and Remdesivir for COVID19 Infections Demonstrates Encouraging Outcomes in Hematopoietic Stem Cell Transplant Recipients: A Single-Center Experience
por: Ionescu, Filip, et al.
Publicado: (2023)

Long-Term Follow-up Outcomes of Patients That Underwent Allogeneic or Autologous Hematopoietic Transplant Shortly after a COVID-19 Infection
por: Marinos, Alejandro, et al.
Publicado: (2023)

Efficacy of Tixagevimab-Cilgavimab in Preventing Sars-Cov-2 in Hematopoietic Stem Cell Transplant and Chimeric Antigen Receptor T-Cell Therapy Recipients
por: McGann, Mary, et al.
Publicado: (2023)

Lessons Learned from COVID-19 Pandemic: Outcomes after Sars-Cov-2 Infection in Hematopoietic Cell Transplant and Cell Therapy Recipients
por: Mushtaq, Muhammad Umair, et al.
Publicado: (2023)

Clinical Presentation and Outcomes of COVID-19 Following Hematopoietic Cell Transplantation
por: Camargo, Jose F., et al.
Publicado: (2021)

Response to Vaccination with Sars-CoV2 Vaccines in Patients Post Allogeneic Hematopoietic Cell Transplantation
por: Pabst, Caroline, et al.
Publicado: (2022)

A Portrait of Sars-Cov-2 Infection in Patients Undergoing Hematopoietic Cell Transplantation: A Systematic Review of the Literature
por: Bailey, Adrian, et al.
Publicado: (2022)

Outcomes of COVID-19 Infection in Allogeneic Hematopoietic Stem Cell Transplant Patients Treated with Hyperbaric Oxygen: A Case Series
por: Usman, Shireen, et al.
Publicado: (2022)

Efficacy of Sars-Cov-2 Vaccine in Hematopoietic Stem Cell Transplantation and CAR-T Cell Therapy Patients; A Single Study Experience
por: Zhuang, Eric, et al.
Publicado: (2022)

Stool Screening for Sars-Cov-2 RNA for COVID-19 in Patients Undergoing Hematopoietic Cell Transplantation, Cellular Therapy, and Induction Chemotherapy
por: Severyn, Christopher J., et al.
Publicado: (2023)

Humoral Immunogenicity of Sars-Cov-2 Vaccination in the First Year after Hematopoietic Cell Transplant or Chimeric Antigen Receptor T Cell Therapy: A CIBMTR and BMT CTN Study
por: Riches, Marcie L., et al.
Publicado: (2022)

COVID 19 Infection in Autologous Stem Cell Transplant (ASCT) Recipients: a Single Institution Observational Cohort
por: Moreb, Jan S., et al.
Publicado: (2023)

Allogeneic, Off-the-Shelf, Sars-Cov-2-Specific T Cells to Treat High-Risk Patients with COVID-19
por: Vasileiou, Spyridoula, et al.
Publicado: (2021)

Transplant Providers’ Perceptions of COVID-19 Vaccination in the Wake of a Global Pandemic
por: Spallone, Amy, et al.
Publicado: (2022)

Vaccination Against Sars-Cov-2 Induces Robust Humoral Immune Response in Patients with Previous Hematologic Stem Cell Transplantation
por: Roldan, Elisa, et al.
Publicado: (2022)

Bamlanivimab Monoclonal Antibody Treatment in Patients with Graft Versus Host Disease (GVHD) Diagnosed with COVID-19 Infection
por: Faisal, Muhammad Salman, et al.
Publicado: (2022)

Humoral Response to COVID-19 Vaccination Given Pre-Cellular Therapy Wanes in Patients after Cellular Therapy: An Argument for Full Reimmunization
por: Shah, Gunjan L., et al.
Publicado: (2022)

Manufacture, Immunological Characterization and Clinical Response of GMP Grade Sars-COV-2 Cytotoxic T Lymphocytes (CTLs) Utilizing the Clinimacs® Cytokine Capture System
por: Chu, Yaya, et al.
Publicado: (2023)

Community Acquired Respiratory Viral Infections (CARV) in Patients with Acute Leukemia and Hematopoietic Stem Cell Transplant (HSCT) Recipients
por: Trikha, Gaurav, et al.
Publicado: (2016)

Evaluation of Cyclosporine Pharmacokinetic, Monitoring, and Dosing Parameters for GVHD Prophylaxis in Hematopoietic Stem Cell Transplant (HSCT) Recipients
por: Tafazoli, Ali, et al.
Publicado: (2019)

Cost Analysis of the Use of Voriconazole, Posaconazole and Micafungin in the Primary Prophylaxis of Invasive Fungal Infections in Recipients of Allogeneic Hematopoietic Stem Cell Transplants
por: Grau, Santiago, et al.
Publicado: (2015)

Pre-exposure prophylaxis with 300 mg Evusheld elicits limited neutralizing activity against the Omicron variant
por: Benotmane, Ilies, et al.
Publicado: (2022)

Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld) for COVID-19 among 1112 severely immunocompromised patients
por: Nguyen, Yann, et al.
Publicado: (2022)

P57 PRE-EXPOSURE PROPHYLAXIS FOR COVID-19 WITH TIXAGEVIMAB/CILGAVIMAB (EVUSHELD) IN PATIENTS WITH MULTIPLE MYELOMA
por: Ntanasis-Stathopoulos, I., et al.
Publicado: (2023)

Safety and efficacy of pre-exposure prophylaxis with tixagevimab/cilgavimab (Evusheld) in patients with glomerular diseases who received rituximab
por: Sciascia, Savino, et al.
Publicado: (2023)

2737. Real World Evaluation of Antifungal Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant (aHSCT) Patients, Is Routine Antifungal Prophylaxis Needed?
por: Perreault, Sarah, et al.
Publicado: (2023)

The ACE2 Receptor for COVID-19 Entry Is Expressed on the Surface of Hematopoietic Stem/Progenitor Cells and Endothelial Progenitors As Well As Their Precursor Cells and Becomes Activated in Nlrp3 Inflammasome-Dependent Manner By Virus Spike Protein - a Potential Pathway Leading to a “Cytokine Storm”
por: Kucia, Magdalena, et al.
Publicado: (2020)

A Critical Analysis of the Use of Cilgavimab plus Tixagevimab Monoclonal Antibody Cocktail (Evusheld™) for COVID-19 Prophylaxis and Treatment
por: Focosi, Daniele, et al.
Publicado: (2022)

Tixagevimab and Cilgavimab (Evusheld™) Prophylaxis Prevents Breakthrough COVID-19 Infections in Immunosuppressed Population: 6-Month Prospective Study
por: Jakimovski, Dejan, et al.
Publicado: (2023)

Establishing the hematopoietic stem cell transplant (HSCT) in a developing country; the journey of HSCT in Semarang, Indonesia
por: Santosa, Damai, et al.
Publicado: (2020)

The clinical course of COVID-19 in hematopoietic stem cell transplantation (HSCT) recipients
por: KARATAŞ, Ayşe, et al.
Publicado: (2021)

Tuberculosis in Pediatric Solid Organ and Hematopoietic Stem Cell Recipients
por: Dubois, Melanie, et al.
Publicado: (2021)

COVID-19 and HSCT (Hematopoietic stem cell transplant)
por: Strasfeld, Lynne
Publicado: (2022)

Use of micafungin as antifungal prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) in Spain (GETH-MIC)
por: López-Sánchez, Cristina, et al.
Publicado: (2020)

(1200) Evusheld Protects Against SARS-CoV-2 in Lung Transplant Recipients
por: Eck, D., et al.
Publicado: (2023)

452 Pseudo-Outbreak of Fulminant Toxoplasmosis in Hematopoietic Stem Cell Transplant [HSCT] Recipients
por: Isa, Flonza, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_oqquhgulahmc8tu0aphhadkd7i